Virtual Library
Start Your Search
Xiaoling Chen
Author of
-
+
P09 - Health Services Research/Health Economics - Real World Outcomes (ID 121)
- Event: WCLC 2020
- Type: Posters
- Track: Health Services Research/Health Economics
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P09.29 - Immune-Related Adverse Events and their Association with Effectiveness of PD-1/PD-L1 Inhibitors in NSCLC: A Real-World Study from China (ID 2086)
00:00 - 00:00 | Presenting Author(s): Xiaoling Chen
- Abstract
Introduction
Programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors are increasingly used in China, but no real-world data are available about the immune-related adverse events (irAEs). This real-world retrospective study aimed to assess the safety and effectiveness of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer (NSCLC) and to analyze the association between irAEs and effectiveness.
Methods
This was a retrospective study of the clinical information of patients with non-small cell lung cancer (NSCLC) treated with PD-1/PD-L1 inhibitors from August 2016 to November 2019 at the Thoracic Medicine of Beijing Cancer Hospital.The patients were divided into irAE or non-irAE groups. Overall adverse events, impact of irAE on tumor response, and association of irAEs with effectiveness were evaluated.
Results
One hundred and ninety-one patients were included in this study, including 70 (36.6%) patients in IrAE Group and 121 (63.4%) patients in Non-irAE Group. AE, grade 3-5 AEs, and IrAE were occurred in 107 (56.0%), 24 (12.6%) and 70 (36.6%) of 191 patients respectively. The objective response rate (ORR) and disease control rate (DCR) were higher in irAE Group compared with Non-irAE Group (42.0% vs. 25.8%, P=0.038; 91.9% vs. 70.8%, P=0.002). Multivariable analyses identified irAE associated with progression-free survival (HR=0.62, 95%CI: 0.43-0.91; P=0.015), but not with overall survival (HR=0.76, 95%CI: 0.44-1.28; P=0.299).
Conclusion
In NSCLC treated with PD-1/PD-L1 inhibitors, patients with irAEs showed improved effectiveness over patients without irAEs. Future studies of anti-PD-1/PD-L1 immunotherapy should address this association to explore the underlying biological mechanisms of efficacy.